Comprehensive in vitro and in silico assessments of metabolic capabilities of 24 genomic variants of CYP2C19 using two different substrates
Introduction: Most hepatically cleared drugs are metabolized by cytochromes P450 (CYPs), and Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines provide curated clinical references for CYPs to apply individual genome data for optimized drug therapy. However, incorporating novel pha...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1055991/full |
| _version_ | 1828066493913366528 |
|---|---|
| author | Myung-Eui Seo Byung-Joo Min Nayoon Heo Kye Hwa Lee Ju Han Kim Ju Han Kim |
| author_facet | Myung-Eui Seo Byung-Joo Min Nayoon Heo Kye Hwa Lee Ju Han Kim Ju Han Kim |
| author_sort | Myung-Eui Seo |
| collection | DOAJ |
| description | Introduction: Most hepatically cleared drugs are metabolized by cytochromes P450 (CYPs), and Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines provide curated clinical references for CYPs to apply individual genome data for optimized drug therapy. However, incorporating novel pharmacogenetic variants into guidelines takes considerable time.Methods: We comprehensively assessed the drug metabolizing capabilities of CYP2C19 variants discovered through population sequencing of two substrates, S-mephenytoin and omeprazole.Results: Based on established functional assays, 75% (18/24) of the variants not yet described in Pharmacogene Variation (PharmVar) had significantly altered drug metabolizing capabilities. Of them, seven variants with inappreciable protein expression were evaluated as protein damaging by all three in silico prediction algorithms, Sorting intolerant from tolerant (SIFT), Polymorphism Phenotyping v2 (PolyPhen-2), and Combined annotation dependent depletion (CADD). The five variants with decreased metabolic capability (<50%) of wild type for either substrates were evaluated as protein damaging by all three in silico prediction algorithms, except CADD exact score of NM_000769.4:c.593T>C that was 19.68 (<20.0). In the crystal structure of the five polymorphic proteins, each altered residue of all those proteins was observed to affect the key structures of drug binding specificity. We also identified polymorphic proteins indicating different tendencies of metabolic capability between the two substrates (5/24).Discussion: Therefore, we propose a methodology that combines in silico prediction algorithms and functional assays on polymorphic CYPs with multiple substrates to evaluate the changes in the metabolism of all possible genomic variants in CYP genes. The approach would reinforce existing guidelines and provide information for prescribing appropriate medicines for individual patients. |
| first_indexed | 2024-04-10T23:31:32Z |
| format | Article |
| id | doaj.art-361a1301b9d74ddba3267d602ff429ad |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-10T23:31:32Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-361a1301b9d74ddba3267d602ff429ad2023-01-12T04:56:14ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-01-011410.3389/fphar.2023.10559911055991Comprehensive in vitro and in silico assessments of metabolic capabilities of 24 genomic variants of CYP2C19 using two different substratesMyung-Eui Seo0Byung-Joo Min1Nayoon Heo2Kye Hwa Lee3Ju Han Kim4Ju Han Kim5Seoul National University Biomedical Informatics (SNUBI), Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South KoreaNational Forensic Service Seoul Institute, Seoul, South KoreaDepartment of Mathematics, University of California, Los Angeles, Los Angeles, CA, United StatesDepartment of Information Medicine, Asan Medical Center and University of Ulsan College of Medicine, Seoul, South KoreaSeoul National University Biomedical Informatics (SNUBI), Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South KoreaSeoul National University Biomedical Informatics (SNUBI), Division of Biomedical Informatics, Seoul National University College of Medicine, Seoul, South KoreaIntroduction: Most hepatically cleared drugs are metabolized by cytochromes P450 (CYPs), and Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines provide curated clinical references for CYPs to apply individual genome data for optimized drug therapy. However, incorporating novel pharmacogenetic variants into guidelines takes considerable time.Methods: We comprehensively assessed the drug metabolizing capabilities of CYP2C19 variants discovered through population sequencing of two substrates, S-mephenytoin and omeprazole.Results: Based on established functional assays, 75% (18/24) of the variants not yet described in Pharmacogene Variation (PharmVar) had significantly altered drug metabolizing capabilities. Of them, seven variants with inappreciable protein expression were evaluated as protein damaging by all three in silico prediction algorithms, Sorting intolerant from tolerant (SIFT), Polymorphism Phenotyping v2 (PolyPhen-2), and Combined annotation dependent depletion (CADD). The five variants with decreased metabolic capability (<50%) of wild type for either substrates were evaluated as protein damaging by all three in silico prediction algorithms, except CADD exact score of NM_000769.4:c.593T>C that was 19.68 (<20.0). In the crystal structure of the five polymorphic proteins, each altered residue of all those proteins was observed to affect the key structures of drug binding specificity. We also identified polymorphic proteins indicating different tendencies of metabolic capability between the two substrates (5/24).Discussion: Therefore, we propose a methodology that combines in silico prediction algorithms and functional assays on polymorphic CYPs with multiple substrates to evaluate the changes in the metabolism of all possible genomic variants in CYP genes. The approach would reinforce existing guidelines and provide information for prescribing appropriate medicines for individual patients.https://www.frontiersin.org/articles/10.3389/fphar.2023.1055991/fullcytochrome P450 2C19 (CYP2C19)mephenytoinomeprazoleCPIC guidelinespharmacogeneticspharmacogenomics |
| spellingShingle | Myung-Eui Seo Byung-Joo Min Nayoon Heo Kye Hwa Lee Ju Han Kim Ju Han Kim Comprehensive in vitro and in silico assessments of metabolic capabilities of 24 genomic variants of CYP2C19 using two different substrates Frontiers in Pharmacology cytochrome P450 2C19 (CYP2C19) mephenytoin omeprazole CPIC guidelines pharmacogenetics pharmacogenomics |
| title | Comprehensive in vitro and in silico assessments of metabolic capabilities of 24 genomic variants of CYP2C19 using two different substrates |
| title_full | Comprehensive in vitro and in silico assessments of metabolic capabilities of 24 genomic variants of CYP2C19 using two different substrates |
| title_fullStr | Comprehensive in vitro and in silico assessments of metabolic capabilities of 24 genomic variants of CYP2C19 using two different substrates |
| title_full_unstemmed | Comprehensive in vitro and in silico assessments of metabolic capabilities of 24 genomic variants of CYP2C19 using two different substrates |
| title_short | Comprehensive in vitro and in silico assessments of metabolic capabilities of 24 genomic variants of CYP2C19 using two different substrates |
| title_sort | comprehensive in vitro and in silico assessments of metabolic capabilities of 24 genomic variants of cyp2c19 using two different substrates |
| topic | cytochrome P450 2C19 (CYP2C19) mephenytoin omeprazole CPIC guidelines pharmacogenetics pharmacogenomics |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1055991/full |
| work_keys_str_mv | AT myungeuiseo comprehensiveinvitroandinsilicoassessmentsofmetaboliccapabilitiesof24genomicvariantsofcyp2c19usingtwodifferentsubstrates AT byungjoomin comprehensiveinvitroandinsilicoassessmentsofmetaboliccapabilitiesof24genomicvariantsofcyp2c19usingtwodifferentsubstrates AT nayoonheo comprehensiveinvitroandinsilicoassessmentsofmetaboliccapabilitiesof24genomicvariantsofcyp2c19usingtwodifferentsubstrates AT kyehwalee comprehensiveinvitroandinsilicoassessmentsofmetaboliccapabilitiesof24genomicvariantsofcyp2c19usingtwodifferentsubstrates AT juhankim comprehensiveinvitroandinsilicoassessmentsofmetaboliccapabilitiesof24genomicvariantsofcyp2c19usingtwodifferentsubstrates AT juhankim comprehensiveinvitroandinsilicoassessmentsofmetaboliccapabilitiesof24genomicvariantsofcyp2c19usingtwodifferentsubstrates |